Data / New clinical trials / Uzbekistan
New clinical trials in Uzbekistan: 33 since Nov 2024
The full list. New clinical trials with a site in Uzbekistan: 33 rows for $5, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. The list gains about 1 row a month. The new rows come each week by email, $19 a month.
$10 of credit on sign-up, no card. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The weekly rows run until you cancel, from the link in each delivery. To get the new rows in your own tools, use SpecStream on Zapier.
For agents and scripts: this list is ordered at https://specstream.ai/data/clinical-trials/country/uzbekistan, and every list with its row count and price is at https://specstream.ai/data/lists.json.
Updated October 16, 2026. Source: ClinicalTrials.gov API v2 (U.S. National Library of Medicine).
33 clinical studies with a site in Uzbekistan were first posted on ClinicalTrials.gov from November 21, 2024 to October 16, 2026; 22 have an industry sponsor and 14 are recruiting or about to. The newest, NCT07879183, was posted on October 16, 2026: Validation of Uzbek-Language ADAM, AMS, and IPSS Questionnaires in Men Aged 35-59 Years (Andijan State Medical Institute).
The request: Every new clinical trial with a site in Uzbekistan, with the sponsor, phase, conditions and the listed contact.
SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.
- 33New trials
- 22Industry sponsored
- 14Recruiting or not yet
- October 16, 2026Latest posted
Newest trials
The newest 33 of 33, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.
| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
|---|---|---|---|---|---|---|---|---|---|
| October 16, 2026 | NCT07879183 | Validation of Uzbek-Language ADAM, AMS, and IPSS Questionnaires in Men Aged 35-59 Years | Andijan State Medical Institute | Observational | Recruiting | Psychometric Validation of Men's Health Questionnaires | 400 | Uzbekistan | clinicaltrials.gov |
| October 1, 2026 | NCT07853495 | Aquatic Skill-Efficiency Instruction Versus Classical Learn-to-Swim Instruction in 8-10-Year-Old Novice Swimmers | Scientific Research Institute of Physical Education and Sports | Not applicable | Completed | Swimming Skill Acquisition | 107 | Uzbekistan | clinicaltrials.gov |
| September 9, 2026 | NCT07811024 | First-in-Human Study Using the SiroMax™ Sirolimus-Coated Balloon Catheter as a Percutaneous Transluminal Coronary Angioplasty (PTCA)... | Tonic Medical, Inc. | Not applicable | Recruiting | Coronary Artery Disease, Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart... | 60 | Uzbekistan | clinicaltrials.gov |
| September 9, 2026 | NCT07810335 | Evaluation of FlowMod System While Intermittently Partially Occluding Vena Cava Blood Flow in Subjects With ADHF | FlowMod, Inc. | Not applicable | Not yet recruiting | Acute Decompensated Heart Failure (ADHF) | 30 | Georgia, Uzbekistan | clinicaltrials.gov |
| July 16, 2026 | NCT07707830 | Internal Organ and Musculoskeletal Assessment in Hypothyroidism (HYPOMORPH) | Andijan State Medical Institute | Observational | Recruiting | Hypothyroidism | 500 | Uzbekistan | clinicaltrials.gov |
| June 15, 2026 | NCT07648017 | Resoloy Initial Safety Evaluation | MeKo Manufacturing e.K. | Not applicable | Active not recruiting | CLTI Defined as Rutherford Category 4 or 5, PAOD (Peripheral Arterial Obstructive Disease) | 10 | Uzbekistan | clinicaltrials.gov |
| April 23, 2026 | NCT07548151 | Guided Needle Insertion for Vascular Access | X9, Inc. | Not applicable | Completed | End Stage Renal Failure, Hemodialysis, Cannulation | 10 | Uzbekistan | clinicaltrials.gov |
| April 17, 2026 | NCT07536724 | First-in-man Trial to Assess the Safety, Performance and Clinical Benefit of the TRICENTO G2 Transcatheter Valve System for Tricuspid... | Medira GmbH | Not applicable | Recruiting | Symptomatic Tricuspid Regurgitation (TR) Graded as Severe or Greater | 10 | Uzbekistan | clinicaltrials.gov |
| April 13, 2026 | NCT07524140 | A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors | Eilean Therapeutics | Phase 1 | Recruiting | Advanced Solid Tumor Cancer, Metastatic Solid Tumor | 60 | Australia, Uzbekistan | clinicaltrials.gov |
| April 7, 2026 | NCT07516158 | Vitamin D and Immune Response in Pulmonary Tuberculosis With and Without Chronic Pulmonary Aspergillosis | Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan | Observational | Active not recruiting | Pulmonary Tuberculoses, Chronic Pulmonary Aspergillosis, Healthy Participants | 300 | Uzbekistan | clinicaltrials.gov |
| March 17, 2026 | NCT07476222 | Anthropometric, Functional and Lifestyle Factors Associated With Testosterone Levels in Middle-Aged Men | Andijan State Medical Institute | Observational | Recruiting | Testosterone Deficiency, Male Hypogonadism | 600 | Uzbekistan | clinicaltrials.gov |
| February 27, 2026 | NCT07435324 | A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell... | R-Pharm | Phase 3 | Completed | Head and Neck Squamous Cell Carcinoma | 161 | Russia, Uzbekistan | clinicaltrials.gov |
| January 15, 2026 | NCT07343856 | Long COVID Diagnostic Reactivity Assesment Test | Oncology Center,Ministry Of Heath,Uzbekistan | Not applicable | Enrolling by invitation | Long COVID, Post-Acute Sequelae of SARS-CoV-2 Infection | 50 | Uzbekistan | clinicaltrials.gov |
| January 9, 2026 | NCT07330752 | First-in-Human Trial of the A3-Shield System for Stabilizing Abdominal Aortic Aneurysms | Angiolutions GmbH | Not applicable | Recruiting | Aneurysm, Abdominal Aortic | 12 | Uzbekistan | clinicaltrials.gov |
| January 8, 2026 | NCT07325682 | Diagnostic Evaluation of Viral Persistence in Cervical Cancer | Oncology Center,Ministry Of Heath,Uzbekistan | Not applicable | Enrolling by invitation | Cervical Cancer | 30 | Uzbekistan | clinicaltrials.gov |
| January 6, 2026 | NCT07319780 | Fibrin-Enhanced TIP Versus Grafted TIP Urethroplasty in Distal Hypospadias | National Children's Medical Center, Uzbekistan | Not applicable | Recruiting | Distal Hypospadias, Hypospadias | 100 | Indonesia, Uzbekistan | clinicaltrials.gov |
| December 26, 2025 | NCT07303660 | A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients | Lomond Therapeutics Holdings, Inc. | Phase 1 | Recruiting | Acute Myeloid Leukemia | 66 | Russia, Uzbekistan | clinicaltrials.gov |
| December 23, 2025 | NCT07298330 | A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) | Mirum Pharmaceuticals, Inc. | Phase 3 | Active not recruiting | Chronic Hepatitis D Infection | 80 | Belgium, Bulgaria, Georgia, Hungary, Israel, Pakistan, Taiwan, Ukraine, United... | clinicaltrials.gov |
| December 19, 2025 | NCT07294612 | Use of Platelet-Rich Fibrin in Bladder Exstrophy Repair | National Children's Medical Center, Uzbekistan | Not applicable | Completed | Bladder Exstrophy-Epispadias Complex | 20 | Uzbekistan | clinicaltrials.gov |
| November 21, 2025 | NCT07241884 | SakuraBead Used as Resorbable Embolic for Plantar Fascia Embolization | CrannMed | Not applicable | Recruiting | Plantar Fascitis, Heel Pain, Musculoskeletal Diseases | 45 | Uzbekistan | clinicaltrials.gov |
| November 19, 2025 | NCT07234864 | Study to Assess Safety, Tolerability, PK, and PD of Multiple Doses of ZE63-0302 Administrated Orally in T2DM Patients. | Eilean Therapeutics | Phase 1 | Active not recruiting | Type 2 Diabetes | 60 | Australia, New Zealand, Uzbekistan | clinicaltrials.gov |
| October 1, 2025 | NCT07200908 | A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) | Mirum Pharmaceuticals, Inc. | Phase 3 | Recruiting | Chronic Hepatitis D Infection | 172 | Austria, Czechia, France, Germany, Italy, Pakistan, Romania, Spain, Sweden... | clinicaltrials.gov |
| September 5, 2025 | NCT07157007 | Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19 | Traws Pharma, Inc. | Phase 2 | Completed | COVID - 19 | 93 | Uzbekistan | clinicaltrials.gov |
| July 24, 2025 | NCT07082426 | Early System Experience With the Abbott Balloon-expandable TAVI System: First-In-Human Study | Abbott Medical Devices | Not applicable | Active not recruiting | Symptomatic Severe Aortic Stenosis | 8 | Georgia, Uzbekistan | clinicaltrials.gov |
| July 15, 2025 | NCT07066540 | Trial of the Efficacy and Safety of Use of Drug Product Reamberin® for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6... | POLYSAN Scientific & Technological Pharmaceutical Company | Observational | Recruiting | Viral Enteric Infection | 300 | Russia, Uzbekistan | clinicaltrials.gov |
| July 1, 2025 | NCT07045545 | A Multicenter Randomized Controlled Trial Comparing Platelet-Rich Fibrin and Ventral Dartos Flap as Intermediate Layers in Tabularized... | National Children's Medical Center, Uzbekistan | Not applicable | Enrolling by invitation | PRF, Hypospadias, Distal Hypospadias, Hypospadias Repair, Fistula Stenosis, Cosmetic Outcomes, Functional Outcomes... | 5 | Uzbekistan | clinicaltrials.gov |
| May 14, 2025 | NCT06971068 | Vacuum-assisted Laser Ablation (VALA) for Treatment of Large Saphenous Veins | Center Of Phlebology | Not applicable | Recruiting | Varicose Veins | 184 | Belarus, Kyrgyzstan, Russia, Uzbekistan | clinicaltrials.gov |
| May 7, 2025 | NCT06960239 | Safety and Efficacy of the Irreversible Electroporation (IRE) System for Adenotonsillar Hypertrophy in Children | ENTire Medical Ltd. | Not applicable | Completed | Tonsillar Hypertrophy, Upper Airway Obstruction | 31 | Romania, Uzbekistan | clinicaltrials.gov |
| March 17, 2025 | NCT06880133 | Expansion of SCG/GCG-Based CAD Sceering: Inclusion of Healthy Controls and CCTA Patients | Heart Force Medical Inc. | Not applicable | Completed | Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) | 1,600 | Uzbekistan | clinicaltrials.gov |
| March 17, 2025 | NCT06880120 | Diagnostic Accuracy Of Seismocardiography for Coronary Artery Disease | Heart Force Medical Inc. | Not applicable | Completed | Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) | 1,534 | Uzbekistan | clinicaltrials.gov |
| February 19, 2025 | NCT06834490 | Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia | Pharmasoft | Phase 3 | Completed | Chronic Cerebral Ischemia | 318 | Russia, Uzbekistan | clinicaltrials.gov |
| December 5, 2024 | NCT06718478 | First in Human Study of SakuraBead for Genicular Artery Embolization to Treat Pain Secondary to Knee Osteoarthritis | CrannMed | Not applicable | Completed | Osteoarthritis (OA) of the Knee, Osteoarthritis Knee Pain, Joint Diseases, Musculoskeletal Diseases, Rheumatic... | 15 | Uzbekistan | clinicaltrials.gov |
| November 21, 2024 | NCT06700226 | AblaView® Unipolar PFA OCR-guided Feasibility Study - First in Man | Medlumics | Not applicable | Completed | Paroxysmal AF | 10 | Uzbekistan | clinicaltrials.gov |
Sponsors posting most
| Sponsor | New trials | Latest |
|---|---|---|
| Andijan State Medical Institute | 3 | October 16, 2026 |
| National Children's Medical Center, Uzbekistan | 3 | January 6, 2026 |
| Eilean Therapeutics | 2 | April 13, 2026 |
| Oncology Center,Ministry Of Heath,Uzbekistan | 2 | January 15, 2026 |
| Mirum Pharmaceuticals, Inc. | 2 | December 23, 2025 |
| CrannMed | 2 | November 21, 2025 |
| Heart Force Medical Inc. | 2 | March 17, 2025 |
| Scientific Research Institute of Physical Education and Sports | 1 | October 1, 2026 |
| Tonic Medical, Inc. | 1 | September 9, 2026 |
| FlowMod, Inc. | 1 | September 9, 2026 |
| MeKo Manufacturing e.K. | 1 | June 15, 2026 |
| X9, Inc. | 1 | April 23, 2026 |
| Medira GmbH | 1 | April 17, 2026 |
| Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan | 1 | April 7, 2026 |
| R-Pharm | 1 | February 27, 2026 |
| Angiolutions GmbH | 1 | January 9, 2026 |
| Lomond Therapeutics Holdings, Inc. | 1 | December 26, 2025 |
| Traws Pharma, Inc. | 1 | September 5, 2025 |
| Abbott Medical Devices | 1 | July 24, 2025 |
| POLYSAN Scientific & Technological Pharmaceutical Company | 1 | July 15, 2025 |
Conditions
| Condition group | New trials | Latest |
|---|---|---|
| Coronary Artery Disease | 3 | September 9, 2026 |
| Angina Pectoris | 3 | September 9, 2026 |
| Myocardial Infarction | 3 | September 9, 2026 |
| Motor Activity | 2 | July 16, 2026 |
| Sarcopenia | 2 | July 16, 2026 |
| Hypospadias | 2 | January 6, 2026 |
| Hepatitis D | 2 | December 23, 2025 |
| Musculoskeletal Diseases | 2 | November 21, 2025 |
| Coronary Stenosis | 1 | September 9, 2026 |
| Hypothyroidism | 1 | July 16, 2026 |
| Renal Insufficiency, Chronic | 1 | April 23, 2026 |
| Tricuspid Valve Insufficiency | 1 | April 17, 2026 |
| Heart Diseases | 1 | April 17, 2026 |
| Neoplasm Metastasis | 1 | April 13, 2026 |
| Glioblastoma | 1 | April 13, 2026 |
| Tuberculosis, Pulmonary | 1 | April 7, 2026 |
| Tuberculosis | 1 | April 7, 2026 |
| Eunuchism | 1 | March 17, 2026 |
| Sleep Initiation and Maintenance Disorders | 1 | March 17, 2026 |
| Squamous Cell Carcinoma of Head and Neck | 1 | February 27, 2026 |
| Post-Acute COVID-19 Syndrome | 1 | January 15, 2026 |
| Primary Dysautonomias | 1 | January 15, 2026 |
| Aortic Aneurysm, Abdominal | 1 | January 9, 2026 |
| Uterine Cervical Neoplasms | 1 | January 8, 2026 |
| Leukemia, Myeloid, Acute | 1 | December 26, 2025 |
By phase
| Phase | New trials | Latest |
|---|---|---|
| Not applicable | 20 | October 1, 2026 |
| Observational | 5 | October 16, 2026 |
| Phase 3 | 4 | February 27, 2026 |
| Phase 1 | 3 | April 13, 2026 |
| Phase 2 | 1 | September 5, 2025 |
Where the register publishes
U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.
$10 of credit on sign-up, no card.